Effect of ropivacaine concentration on duration for interscalene blocks given for arthroscopic shoulder surgery: a prospective randomised controlled trial

Phase 4

Completed

• Conditions: Shoulder arthroscopic surgery analgesia; Anaesthesiology - Pain management

• Registration Number: ACTRN12611000433909
• Lead Sponsor: Dr Jason Koerber

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-04-27
• Study Completion: 2016-12-23
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

Elective arthroscopic shoulder surgery
Age 18-80 years
ASA 1-3

Exclusion Criteria

Patient refusal

Previous involvement in this study

Contraindication to interscalene block (patient refusal, coagulopathy, sepsis, local infection, severe respiratory disease, allergy to ropivacaine)

Upper limb neurological disease or deficits

Opioid tolerance (defined as use of >30mg oral morphine/day or equivalent – fentanyl patch 12mcg/hr, buprenorphine 20mcg/hr, oxycodone >20mg/day)

Contraindication to COX2 inhibitors/NSAIDs (renal impairment, NSAIDs/aspirin trigger asthma, active peptic ulcer disease, or allergy).

Study & Design

• Study Type: Interventional
• Study Design: Not specified